

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

FOSUN 复星

復星國際有限公司
FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 00656)

JOINT ANNOUNCEMENT

**DISCLOSEABLE TRANSACTION — COMPLETION OF THE ACQUISITION OF
THE CONTROLLING INTEREST IN GLAND PHARMA LIMITED**

References are made to the joint announcements dated 28 July 2016, 24 April 2017, 27 July 2017 and 17 September 2017 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“**Fosun Pharma**”) and Fosun International Limited (“**Fosun International**”), the controlling shareholder of Fosun Pharma, the announcements of Fosun Pharma dated 4 August 2016, 30 March 2017 and 1 August 2017, the circular of Fosun Pharma dated 11 August 2016 (the “**Circular**”) and the poll results announcement of Fosun Pharma dated 29 September 2016 in connection with, among other things, acquiring the controlling interest in Gland Pharma Limited (“**Gland Pharma**”). Unless otherwise specified, capitalized terms used herein shall have the same meanings ascribed to them in the Circular.

Since all conditions precedent of the acquisition of the controlling interest in Gland Pharma have been satisfied, in accordance with the terms of the Transaction Documents and the amendments thereto, the boards of directors of Fosun Pharma and Fosun International are pleased to announce that the completion of the acquisition of the controlling interest in Gland Pharma took place on 3 October 2017 (the “**Completion**”).

Following the Completion, Gland Pharma becomes an indirect non-wholly owned subsidiary of Fosun Pharma and Fosun International (Fosun Pharma and Fosun International (via Fosun Pharma) indirectly hold approximately 74% equity interest in Gland Pharma), and the financial results of Gland Pharma will be consolidated into the financial statements of Fosun Pharma and Fosun International.

By order of the board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

By order of the board
Fosun International Limited
Guo Guangchang
Chairman

3 October 2017

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of Fosun Pharma are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors of Fosun Pharma are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors of Fosun International are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.

** For identification purposes only*